Extended Data Table 3 Ad hoc analysis of tumor responses per RECIST v1.1 in patients with measurable disease in cohort 4B by CLDN18.2 expressiona and PD-L1 CPS

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  1. aOne patient was missing a value for CLDN18.2 expression. Two patients were missing PD-L1 CPS values.
  2. bDefined as ≥75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  3. cDefined as ≥50% to <75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  4. BOR, best overall response; CI, confidence interval; CLDN18, claudin 18; CLDN18.2, claudin 18 isoform 2; CR, complete response; DCR, disease control rate; DOR, duration of response; IHC, immunohistochemistry; NE, not estimable; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.
Back to article page